

Neurology Publish Ahead of Print

DOI: 10.1212/WNL.000000000201122

Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis: Analysis of the ACTION-CVT Study

Author(s):

Liqi Shu, MD¹; Ekaterina Bakradze, MD²; Setareh Salehi Omran, MD³; James Giles, MD⁴; Jordan Amar, MD⁴; Nils Henninger, MD^{5,6}; Marwa elnazeir, MD⁵; Ava Liberman, MD⁷; Khadean Moncrieffe, BS⁸; Jenny Rotblat, MD⁸; Richa Sharma, M.D., M.P.H.⁹; Yee Cheng, MD⁹; Adeel S Zubair, MD⁹; Alexis Simpkins, MD¹⁰; Grace Li, MD¹⁰; Justin Kung¹⁰; Dezaray Perez, MD¹⁰; Mirjam R Heldner, MD MSc¹¹; Adrian Scutelnic, MD¹¹; Rascha von Martial, md¹¹; Bernhard Siepen, MD¹¹; Aaron Rothstein, MD¹²; Ossama Khazaal, MD¹²; David Do, MD¹²; Sami Al Kasab, MD^{13,14}; Line Abdul Rahman, MD¹³; Eva A. Mistry, MD¹⁵; Deborah Kerrigan, MD¹⁶; Hayden Lafever¹⁶; Thanh N. Nguyen, MD, FRCPC¹⁷; Piers Klein¹⁷; Hugo J. Aparicio, MD, MPH¹⁷; Jennifer A. Frontera, MD¹⁸; Lindsey Kuohn, BS¹⁸; Shashank Agarwal, MD¹⁸; Christoph Stretz, MD¹; Narendra Kala, MD¹; Sleiman ElJamal, MD¹; Allison Chang¹; Shawna Cutting, MD¹; Fransisca Indraswari, MD¹; Adam de Havenon, MD⁹; Varsha Muddasani, MD¹⁹; Teddy Wu, MD²⁰; Duncan Wilson, PhD²⁰; Amre Nouh, MD²¹; Daniyal Asad, MD²¹; Abid Qureshi, MD²²; Justin Moore, MD²²; Pooja Khatri, MD¹⁵; Yasmin Aziz, MD¹⁵; Bryce Casteigne, MD¹⁵; Muhib Khan, MD²³; Yao Cheng, MD²³; Brian Mac Grory, MD²⁴; Martin Weiss, MD²⁴; Dylan Ryan, MD²⁴; Maria Cristina Vedovati, MD²⁵; Maurizio Paciaroni, MD²⁶; James Siegler, MD²⁷; Scott Kamen, MD²⁷; Siyuan Yu, MD²⁷; Christopher Leon Guerrero, MD²⁸; Eugenie Atallah, MD²⁸; Gian Marco De Marchis, MD²⁹; Alex Brehm, MD³⁰; Tolga Ditrach, MD²⁹; Marios Psychogios, MD³⁰; Ronald Alvarado-Dyer, MD³¹; Tareq Kass-Hout, MD³¹; Shyam Prabhakaran, MD³¹; Tristan Honda, MD³²; David Liebeskind, MD³²; Karen Furie, MD¹; Shadi Yaghi, MD¹

Corresponding Author:

Shadi Yaghi, shadiyaghi@yahoo.com

Neurology[®] Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.

Copyright © 2022 American Academy of Neurology. Unauthorized reproduction of this article is prohibited

Affiliation Information for All Authors: 1. Department of Neurology, Brown University, Providence, RI, USA; 2. Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA; 3. Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA; 4. Department of Neurology, Washington University, Saint Louis, MO, USA; 5. Department of Neurology, University of Massachusetts, Worcester, MA, USA; 6. Department of Psychiatry, University of Massachusetts, Worcester, MA, USA; 7. Department of Neurology, Weill Cornell Medical Center, New York, NY, USA; 8. Department of Neurology, Montefiore Medical Center, New York, NY, USA; 9. Department of Neurology, Yale University, New Haven, CT, USA; 10. Department of Neurology, University of Florida, Gainesville, FL, USA; 11. Department of Neurology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland; 12. Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA; 13. Department of Neurology, Medical University of South Carolina, Charleston, SC, USA; 14. Department of Neurosurgery, Medical University of South Carolina, Charleston, SC, USA; 15. University of Cincinnati, Department of Neurology and Rehabilitation Medicine; 16. Department of Neurology, Vanderbilt University, Nashville, TN, USA; 17. Department of Neurology, Boston University School of Medicine, Boston, MA, USA; 18. Department of Neurology, New York University, New York, NY, USA; 19. Department of Neurology, University of Utah, Salt Lake City, UT, USA; 20. Department of Neurology, Christchurch hospital, Christchurch, New Zealand; 21. Department of Neurology, Hartford Hospital, Hartford, CT, USA; 22. Department of Neurology, University of Kansas, Kansas City, KS, USA; 23. Department of Neurology, Spectrum Health, Michigan State University, Grand Rapids, MI, USA; 24. Department of Neurology, Duke University, Durham, NC, USA; 25. Department of Medicine and Surgery, University of Perugia, Perugia, Italy; 26. Neurology – Stroke Unit, IRCCS MultiMedica, Milano, Italy; 27. Cooper Neurologic Institute, Cooper University, Camden, NJ, USA; 28. Department of Neurology, George Washington University, District of Columbia, USA; 29. Department of Neurology, University Hospital Basel and University of Basel, Switzerland; 30. Department of interventional and diagnostic Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel and University of Basel, Switzerland; 31. Department of Neurology, University of Chicago, Chicago, IL, USA; 32. Department of Neurology, University of California at Los Angeles, Los Angeles, CA, USA

Equal Author Contribution:

Contributions:

Liqi Shu: Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data
Ekaterina Bakradze: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Setareh Salehi Omran: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

James Giles: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jordan Amar: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Nils Henninger: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Marwa elnazeir: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ava Liberman: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Khadean Moncrieffe: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jenny Rotblat: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Richa Sharma: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Yee Cheng: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Adeel S Zubair: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Alexis Simpkins: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Grace Li: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Justin Kung: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition

of data

Dezaray Perez: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Mirjam R Heldner: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Adrian Scutelnic: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Rascha von Martial: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Bernhard Siepen: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Aaron Rothstein: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ossama Khazaal: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

David Do: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Sami Al Kasab: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Line Abdul Rahman: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Eva A. Mistry: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Deborah Kerrigan: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Hayden Lafever: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Thanh N. Nguyen: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Piers Klein: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Hugo J. Aparicio: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Jennifer A. Frontera: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Lindsey Kuohn: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Shashank Agarwal: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Christoph Stretz: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Narendra Kala: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Sleiman ElJamal: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Allison Chang: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Shawna Cutting: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Fransisca Indraswari: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Adam de Havenon: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Varsha Muddasani: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Teddy Wu: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Duncan Wilson: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Amre Nouh: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Daniyal Asad: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the

acquisition of data

Abid Qureshi: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Justin Moore: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Pooja Khatri: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Yasmin Aziz: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Bryce Casteigne: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Muhib Khan: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Yao Cheng: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Brian Mac Grory: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Martin Weiss: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Dylan Ryan: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Maria Cristina Vedovati: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Maurizio Paciaroni: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

James Siegler: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Scott Kamen: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Siyuan Yu: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Christopher Leon Guerrero: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Eugenie Atallah: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Gian Marco De Marchis: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Alex Brehm: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Tolga Dittrich: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Marios Psychogios: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Ronald Alvarado-Dyer: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Tareq Kass-Hout: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Shyam Prabhakaran: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Tristan Honda: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

David Liebeskind: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Karen Furie: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data

Shadi Yaghi: Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

Figure Count:

1

Table Count:

2

Search Terms:

[2] All Cerebrovascular disease/Stroke, [345] Equity, Diversity, and Inclusion (EDI)

Acknowledgment:**Study Funding:**

This work has been supported partially by the Italian Ministry of Health Ricerca Corrente – IRCCS MultiMedica.

Disclosures:

A. Scutelnic has received research support from Swiss Heart Foundation, not related to the present work. T. Nguyen reports research support from Medtronic and the Society of Vascular and Interventional Neurology (unrelated). P. Khatri reports funds from Bayer for effort as National USA Leader of the Bayer PACIFIC-Stroke trial. M. Khan reports research support from National Institute of Neurological Diseases and Stroke (NINDS) (unrelated). M. Paciaroni receives speaker honoraria from Sanofi-Aventis; Boehringer-Ingelheim, Bayer, BMS, Daiichi-Sankyo, Pfizer. G.M. De Marchis reports consultant's and travel honoraria by Bayer; payments were made to the research fund of the University Hospital of Basel, Switzerland. The other authors report no relevant disclosures. All other authors reports no relevant disclosures.

Preprint DOI:**Received Date:**

2022-03-01

Accepted Date:

2022-07-01

Handling Editor Statement:

Submitted and externally peer reviewed. The handling editor was José Merino, MD, MPhil, FAAN.

Abstract

Background and Purpose

Cerebral venous thrombosis (CVT) is a rare cause of stroke carrying a nearly 4% risk of recurrence after 1 year. There is limited data on predictors of recurrent venous thrombosis in patients with CVT. In this study, we aim to identify those predictors.

Methods

This is a secondary analysis of the ACTION-CVT study which is a multi-center international study of consecutive patients hospitalized with a diagnosis of CVT over a 6-year period. Patients with cancer associated CVT, CVT during pregnancy, or CVT in the setting of known antiphospholipid antibody syndrome were excluded per the ACTION-CVT protocol. The study outcome was recurrent venous thrombosis defined as recurrent venous thromboembolism (VTE) or de-novo CVT. We compared characteristics between patients with vs. without recurrent venous thrombosis during follow-up and performed adjusted Cox regression analyses to determine important predictors of recurrent venous thrombosis.

Results

947 patients were included with a mean age was 45.2 years, 63.9% were women, and 83.6% had at least 3-months of follow-up. During a median follow-up of 308 (IQR 120-700) days, there were 5.05 recurrent venous thromboses (37 VTE and 24 *de-novo* CVT) per 100 patient-years. Predictors of recurrent venous thrombosis were Black race (adjusted HR 2.13, 95% CI 1.14-3.98, $p = 0.018$), prior history of VTE (aHR 3.40, 95% CI 1.80-6.42, $p < 0.001$) and the presence of one or more positive antiphospholipid antibodies (aHR 3.85, 95% CI 1.97-7.50, $p < 0.001$). Sensitivity analyses including events only occurring on oral anticoagulation yielded similar findings.

Conclusion

Black race, history of VTE, and the presence of one or more antiphospholipid antibodies are associated with recurrent venous thrombosis among patients with CVT. Future studies are needed to validate our findings to better understand mechanisms and treatment strategies in patients with CVT.

Introduction

Cerebral venous thrombosis (CVT) is an uncommon cause of stroke, usually affecting younger patients¹, patients with thrombophilia, and women who are pregnant, post-partum, or receiving oral contraceptives.² The annual incidence is estimated to be nearly 10-20 cases per million.³⁻⁶ In the absence of contraindications, parenteral followed by oral anticoagulation is the recommended treatment.⁷

In patients with venous thromboembolism (VTE), trials showed a recurrence of about 3-5% per year on anticoagulation therapy.⁸⁻¹⁰ There is limited data about the equivalent risk in patients with CVT, particularly in modern patient cohorts. For instance, the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) showed a recurrence rate of 4.0% at 1 year and 6.5% at 2 years¹¹ but only 41.5% were on anticoagulation at the time of the recurrence.¹² Two other observational studies showed a risk of VTE recurrence after CVT between 2.4-3.5 events per 100 patient-years.^{13,14} The RE-SPECT CVT trial compared dabigatran to warfarin and showed no recurrent VTE at 24 weeks in either group.¹⁵ Therefore, studies evaluating predictors of recurrent venous thrombosis after CVT are limited by the low event rate and further confounded by inconsistent use of anticoagulation at the time of recurrence.^{2,12,15}

Investigating predictors of recurrent events are important to help identify high risk groups for further study and closer follow up. In addition, a better understanding of the predictors of events occurring on anticoagulation is a prerequisite to improve treatment strategies.

Prior studies have found that racial and ethnic disparities affect outcomes in stroke patients²⁰⁻²³, but very limited research had similar finding in CVT population.²⁴ This is particularly important in CVT as the feasibility of treatments such as DOACs and access to care for INR checks with warfarin are altered by socioeconomic factors. Since these are crucial to reduce the risk VTE recurrence after CVT we included social determinants of health such as race and ethnicity among the potential predictors of recurrence.

In this study, we sought to identify risk factors for recurrent VTE in a modern CVT population from a large, multi-center, real world observational study.

Methods

Institutional review board approval was obtained from each participating center to perform the study. De-identified data are available upon reasonable request to the corresponding author.

Patient Population

The “Anticoagulation in the Treatment of Cerebral Venous Thrombosis” (ACTION-CVT) study was a multicenter international retrospective cohort study that included consecutive patients with a confirmed diagnosis of acute CVT from January 1st 2015 to December 31st 2020.¹⁶ Patients were identified using ICD-9 (325.0, 437.6, and 671.5) and ICD-10 codes (I67.6),^{17,18} and were included irrespective of the service they were treated on. These diagnoses were confirmed by review of medical records and imaging studies.

Inclusion and Exclusion Criteria

The ACTION-CVT study aimed to compare direct oral anticoagulants to vitamin K antagonists and collected data on consecutive adult patients hospitalized with CVT confirmed on imaging. To reduce treatment by indication bias, ACTION-CVT excluded patients with CVT during pregnancy, known history of antiphospholipid antibody syndrome, and those with known active cancer.

Study Variables

We collected demographic variables (age, biological sex [Male and Female], self-reported race [Asian, Black, White, Other, Unknown] and ethnicity [Hispanic and Non-Hispanic]), clinical risk factors (body mass index closest to the time of diagnosis, history of prior VTE, active smoking, birth control use, delivery within 12 weeks of diagnosis, and family history of venous thrombosis), presenting symptoms (headache, focal deficit, seizure, encephalopathy or coma), laboratory variables (platelet count, hemoglobin level, one or more antiphospholipid antibodies present at the time of diagnosis but not meeting criteria for antiphospholipid antibody syndrome¹⁹ at the time of index CVT diagnosis, factor V Leiden and/or prothrombin gene mutation) and variables collected during follow up (duration of treatment, duration of follow-up, and available follow up INR checks in patients on warfarin) were obtained. Elevated hemoglobin was defined as hemoglobin >16.5 g/dL in men or >16.0 g/dL in women and elevated platelet was defined as platelet count $\geq 450 \times 10^9/L$. Details of variables are further described in the ACTION-CVT study.¹⁶

Study Outcome

The study outcome was recurrent venous thrombosis (VTE or de-novo CVT) during follow up. Recurrent venous thromboembolism was defined as new deep venous thrombosis

(which involves any deep vein including upper or lower extremities or pelvis), or pulmonary embolism during follow up occurring more than 1 week after CVT diagnosis. The diagnostic methodology for DVT and PE was not collected in our study but generally DVT and PE are clinically suspected and DVT is diagnosed with doppler ultrasound or pelvic MRV and PE is diagnosed with CT angiogram of the chest. The de-novo CVT was defined as new CVT at a distant location from the original CVT or CVT recurrence at the same location in patients with complete recanalization of the initial CVT. Extension of the original CVT was not included in the recurrent venous thrombosis outcome. All outcomes were adjudicated by the individual sites with plausibility checks conducted by the central site and queries sent to confirm outcomes of interest as appropriate.

Analytical Plan

Data verification was conducted by queries to ensure data integrity and consistency. Missing data was not imputed. For univariate analyses, patients were divided into two groups based on whether they had recurrent venous thrombosis. Between-group comparisons were done by t-test, chi-square test, Fisher's exact test, or Wilcoxon Rank-Sum test as appropriate. We then built Cox regression models that included variables associated with recurrent venous thrombosis in univariate analyses ($p < 0.05$) to identify important predictors of recurrent venous thrombosis. Patients were censored at the time of recurrent venous thrombosis, death, or last follow up. Sensitivity analysis was performed with exclusion of events occurring off oral anticoagulation. Kaplan-Meier survival estimates of recurrent venous thrombosis were plotted regarding identified risk factors. Proportionality was assessed using Schoenfeld's residuals. Data were analyzed using Stata (version 15.1) and a $p < 0.05$ was considered statistically significant.

Results

Out of 1025 patients in ACTION-CVT, 67 were excluded due to active cancer and 11 were excluded due to a known diagnosis of antiphospholipid antibody syndrome. Thus, 947 patients were included with a mean age of included subjects was 45.2 years, 63.9% (605) were women. During a median follow-up of 308 (IQR 120-700) days, there were 5.05 recurrent venous thromboses (37 VTE and 24 *de-novo* CVT) per 100 patient-years. Among patients with *de-novo* CVT, only 2 had same site recurrence after complete recanalization of the initial CVT.

At least 3-month follow up was available in 83.6% (792/947) of patients. Compared to patients with <90 days of follow up, patients with ≥ 90 -day follow up data were less likely to be active smokers (12.2% vs. 19.4%, $p = 0.017$). Other characteristics were not significantly different between the two groups and are summarized in Supplementary Table I.

Univariate analyses

In univariate analyses, Black race (28.3% vs. 14.7%, $p = 0.005$), a history of VTE (24.6% vs. 10.0%, $p < 0.001$), encephalopathy or coma upon presentation (36.1% vs 20.5%, $p = 0.004$), lower platelet count (230.6 ± 97.1 vs. 268.7 ± 101.8 , $p = 0.006$), ≥ 1 positive antiphospholipid antibodies (24.0% vs. 8.4%, $p < 0.001$) were associated with recurrent venous thrombosis. Other characteristics did not significantly differ between the two groups (Table 1).

Factors associated with recurrent VTE in Cox regression analysis

In adjusted Cox-regression analyses including variables achieving a statistically significant association ($p < 0.05$) with recurrent venous thrombosis on univariate analyses, predictors of recurrent venous thrombosis were Black race (adjusted HR 2.13, 95% CI 1.14-3.98, $p = 0.018$), history of VTE (adjusted HR 3.40, 95% CI 1.80-6.42, $p < 0.001$) and ≥ 1 positive

antiphospholipid antibodies (adjusted HR 3.85, 95% CI 1.97-7.50, $p < 0.001$). Other variables did not achieve statistical significance.

Sensitivity and exploratory analyses

Sensitivity analyses excluding events that occurred off oral anticoagulation yielded similar findings to the main analysis. In univariate analyses, factors associated with recurrent venous thrombosis were Black race (29.0% vs. 14.1%, $p = 0.034$), prior history of VTE (28.1% vs. 10.2%, $p = 0.005$), and ≥ 1 positive antiphospholipid antibodies (27.6% vs. 9.0%, $p = 0.004$). (Table 2). In adjusted Cox-regression analyses, predictors of recurrent venous thrombosis were Black race (adjusted HR 2.59, 95% CI 1.17-5.75, $p = 0.019$), prior history of VTE (adjusted HR 4.59, 95% CI 2.02-10.43, $p < 0.001$) and ≥ 1 positive antiphospholipid antibodies (adjusted HR 4.26, 95% CI 1.83-9.91, $p = 0.001$). Moreover, Black race, prior history of VTE, and ≥ 1 positive antiphospholipid antibodies continued to be predictors of recurrent venous thrombosis in sensitivity analyses including CVT extension as outcome ($n = 19$) as well as when not counting same site de-novo CVT as outcome.

Furthermore, an additional analysis was performed comparing CVT triggers and availability of appropriate INR checks across different race groups. In this analysis, Black race was associated with a lower rate of expected follow up with INR checks when treated with warfarin (84.2% [64/76] vs 90.6% [423/467], $p = 0.091$). In addition, Black race was associated with decreased prevalence of factor V and/or prothrombin mutation (3/102 [2.9%] vs 71/567 [12.5%], $p = 0.003$). The prevalence of other CVT provoking factors was not significantly different between Black vs. non-Black race: being within 12 weeks post-partum (4.9% [7/143] vs. 3.8% [30/788], $p = 0.490$), recent mastoiditis or sinusitis (8.2% [12/146] vs. 8.6% [68/794], $p = 0.891$), and recent head trauma (4.8% [7/146] vs. 9.1% [72/793], $p = 0.104$). Furthermore, the

association between Black race and recurrent venous thrombosis persisted and the effect size was unchanged after adjustment for factor V and/or prothrombin mutation (adjusted HR 2.34, 95% CI 1.13-4.84, $p = 0.022$).

Discussion

This large, multicenter, international, retrospective, observational study found that, among patients diagnosed with CVT, Black race, a prior history of VTE, and the presence of one or more positive antiphospholipid antibodies were associated with an increased risk of CVT recurrence. These factors were associated with recurrent venous thrombosis in various analyses and models: 1) only including recurrent venous thrombosis events that occurred while on anticoagulation, 2) considering CVT extension as recurrent venous thrombosis outcome, and 3) excluding same site CVT recurrence after complete recanalization from the recurrent venous thrombosis outcome.

These findings contrast with observations from prior studies. For instance, the ISCVT study showed that male sex and polycythemia/thrombocythemia were the only independent predictors of venous thromboembolism after CVT.²⁷ Other multicenter studies found an association between venous thrombosis recurrence and history of prior VTE.^{13,28} A prospective study of 187 patients in France identified previous VTE, presence of cancer or hematological malignancies, and unknown CVT causes as independent risk factors for CVT recurrence.² Our study differs from other studies by using contemporary real world data with different treatment strategies. For instance, in our study, nearly 43% of patients were treated with direct oral anticoagulants. Furthermore, prior large CVT cohorts such as ISCVT were conducted in different patient cohorts which may have led to differences in findings.²⁷

The association between Black race and recurrent venous thrombosis is noteworthy. Consistent with prior studies,^{29,30} our study found that Black race was associated with decreased prevalence of Factor V Leiden and/or prothrombin mutation. However, the association and effect size between Black race and recurrent venous thrombosis remained unchanged even after adjusting for Factor V Leiden and/or prothrombin mutation, suggesting that this difference is not driving the increased risk of recurrent venous thrombosis seen with Black race. The above findings suggest that the association between Black race and recurrent venous thrombosis is likely not the result of biological differences between different races but rather the result of socioeconomic inequities, structural racism, and disparities in access to health care. These disparities have been shown to exist in several aspects of stroke care³¹ and this study shows that they may also exist in patients with CVT. For instance, in our study, Black race was associated with non-significantly lower rates of available follow up INR checks when treated with warfarin, likely a reflection of access to care disparity and decreased availability of health care resources to Black race. Thus, tremendous efforts on multiple levels are needed to address these disparities.³² While our analysis demonstrates that the social construct of race is associated with differences in venous thrombosis recurrent, we cannot disambiguate the contribution of any specific social and/or structural factors driving racial differences in venous thrombosis recurrence.

The associations between a prior history of VTE and the presence of one or more antiphospholipid antibodies and recurrent venous thrombosis are likely due to several reasons. Both factors point to an intrinsic hypercoagulability, either due to a genetic predisposition (in patients with history of VTE) or acquired (antiphospholipid antibodies), which may increase the likelihood of recurrence, even in anticoagulated patients. Current oral anticoagulants are

imperfect. Warfarin, for instance, is limited by fluctuations of anticoagulation levels with a time to therapeutic range ranging between 55-65% in clinical trials and real-world data.^{8-10,33} Furthermore, while DOACs may be effective for CVT treatment in general¹⁵, they have not been extensively studied in patients who have intrinsic hypercoagulability. In fact, in patients with antiphospholipid antibody syndrome, the Rivaroxaban in antiphospholipid syndrome (RAPS) trial showed that rivaroxaban is not non-inferior to warfarin and the Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial found rivaroxaban to be harmful in triple positive cases.^{34,35} Thus, in acute CVT patients with positive antiphospholipid antibodies upon initial evaluation, it may be reasonable to use warfarin pending confirmation of diagnosis upon repeat antibody testing 12 weeks later.³⁶⁻³⁸ In addition, patients with prior VTE may require a more comprehensive diagnostic evaluation, including genetic testing as well as malignancy screening particularly if the prior VTE was recent. This is important as in addition to treatment of the underlying cancer, low molecular weight heparin or DOAC are preferred options in patients with VTE in the setting of active cancer.³⁹⁻⁴¹ Other measures to reduce clotting tendency such as adequate oral hydration and avoidance of medications with increased thrombosis risk such as hormonal contraception should also be considered. Furthermore, close follow up of patients with herein identified risk factors may improve medication adherence and adequate anticoagulation levels.

Strengths and Limitations

Our study has several limitations inherent to its retrospective and observational design. First, approximately 16% of patients were lost to follow up within 90 days. Nevertheless, we performed survival analyses and patients were included and censored at the time of lost to follow up. Furthermore, important variables and recurrent venous thrombosis predictors in our study

and prior studies were similar between patients with vs. without 90 day follow up. Second, similar to prior studies, we observed an overall low recurrence rate of venous thrombosis^{2,15,28}, which may have left our analysis underpowered to identify possible other predictors. Third, we did not have data on several factors including self-reported gender, certain diagnosis such as polycythemia vera and essential thrombosis, and the time in therapeutic range for patients treated with warfarin or medication adherence rates. These factors require further investigation in future studies. That said, polycythemia vera and essential thrombosis, which have been shown to predict VTE recurrence in one study¹¹, are very rare causes of CVT and in our study, however, neither increased platelet count nor increased hemoglobin were associated with increased risk of recurrent venous thrombosis. Fourth, because not all patients had all antiphospholipid antibodies checked and testing was performed in the acute setting, it is possible that patients may have been labeled as falsely negative and others may have been falsely positive. This would however bias the results towards accepting the null hypothesis and is unlikely to impact the results of our study. Fifth, our dataset does not capture the number of positive antibodies which may be important given that in triple positive antiphospholipid antibodies warfarin may be superior to DOACs.^{34,35} Sixth, some patients may have been classified as CVT extension when their CVT may have been a *de-novo* CVT if they had complete recanalization that was not captured on an imaging study after occurrence and prior to extension. These cases are extremely rare as it would be highly improbable that a patient with a known CVT at a certain location and extension at the same site on follow up imaging, to have had complete recanalization between the two scans. Finally, ACTION-CVT excluded patients with CVT in the setting of pregnancy, antiphospholipid antibody syndrome, and active cancer to reduce the risk of treatment by indication bias. Thus, our findings may not be generalizable to the CVT population in general

particularly that some of these conditions confer a high risk of recurrent VTE. Therefore, future studies including patients with such conditions are needed to confirm our findings.

Conclusion

Black race, history of VTE, and the presence of one or more antiphospholipid antibodies are associated with recurrent venous thrombosis as well as breakthrough recurrent venous thrombosis among patients with CVT on anticoagulation therapy. Future studies are needed to validate our findings to better understand mechanisms and treatment strategies in patients with CVT and anticoagulation failure.

ACCEPTED

Table 1. Differences in baseline characteristics and follow up duration across patients with or without venous thrombosis recurrence

	Recurrent venous thrombosis (n = 61)	No Recurrent venous thrombosis (n = 886)	p-value
Age (mean ± SD)	45.69±17.8	45.14±16.63	0.802
Sex (% women)	36/61(59.0%)	569/886(64.2%)	0.413
Race			
Asian*	1/60(1.7%)	38/880(4.3%)	0.507
Black	17/60(28.3%)	129/880(14.7%)	0.005
White	38/60(63.3%)	617/880(70.1%)	0.269
Other*	4/60(6.7%)	96/880(10.9%)	0.390
Ethnicity (% Hispanic)*	6/60(10.0%)	89/879(10.1%)	1.000
Body mass index (mean ± SD)	30.36±7.84	29.42±7.64	0.364
History of VTE	15/61(24.6%)	89/886(10.0%)	0.000
Family history of VTE*	7/61(11.5%)	91/879(10.4%)	0.828
12 weeks post-partum*	0/60(0.0%)	37/878(4.2%)	0.163
Birth control use	11/60(18.3%)	217/869(25.0%)	0.248
Active smoking*	3/61(4.9%)	123/880(14.0%)	0.050
Clinical presentation			
Headache	44/60(73.3%)	676/885(76.4%)	0.591
Focal deficit	26/61(42.6%)	340/885(38.4%)	0.514
Seizure	14/61(23.0%)	210/885(23.7%)	0.890
Encephalopathy or coma	22/61(36.1%)	182/886(20.5%)	0.004
Elevated hemoglobin*	1/59(1.7%)	53/868(6.1%)	0.247
Elevated platelet*	1/59(1.7%)	43/869(4.9%)	0.355
Platelet count (mean SD)	230.59±97.13	268.65±101.84	0.006
One or more positive APL antibody	12/50(24.0%)	62/741(8.4%)	0.000
Factor V and/or prothrombin mutation*	7/39(17.9%)	67/635(10.6%)	0.181
Imaging findings	35/61(57.4%)	500/882(56.7%)	0.916
Venous infarct	13/61(21.3%)	249/882(28.2%)	0.243
Cerebral edema	22/61(36.1%)	270/882(30.6%)	0.373
Intracranial hemorrhage	28/60(46.7%)	342/882(38.8%)	0.226
Duration of treatment to imaging	181(47-370)	178(92-297)	0.592
Available Follow up INR checks for Warfarin treated patients*	34/41(82.9%)	454/504(90.1%)	0.179

* Fisher's exact test was performed, SD = standard deviation, INR = international normalized ratio; VTE = venous thromboembolism


Table 2. Differences in baseline characteristics and follow up duration across patients with or without venous thrombosis recurrence while taking oral anticoagulant

	Recurrent venous thrombosis (n = 32)	No Recurrent venous thrombosis (n = 813)	p-value
Age (mean ± SD)	42.25±17.98	44.93±16.21	0.362
Sex (% women)	20/32(62.5%)	527/813(64.8%)	0.787
Race			
Asian*	1/31(3.2%)	33/807(4.1%)	1.000
Black*	9/31(29.0%)	114/807(14.1%)	0.034
White	19/31(61.3%)	581/807(72.0%)	0.195
Other*	2/31(6.5%)	79/807(9.8%)	0.760
Ethnicity (% Hispanic)*	3/32(9.4%)	79/805(9.8%)	1.000
Body mass index (mean ± SD)	31.44±7.74	29.28±7.52	0.111
History of VTE*	9/32(28.1%)	83/813(10.2%)	0.005
Family history of VTE*	4/32(12.5%)	91/809(11.2%)	0.776
12 weeks post-partum*	1/32(3.1%)	27/804(3.4%)	1.000
Birth control use*	9/32(28.1%)	209/795(26.3%)	0.838
Active smoking*	2/32(6.3%)	109/809(13.5%)	0.298
Clinical presentation			
Headache*	25/31(80.6%)	639/812(78.7%)	1.000
Focal deficit	11/32(34.4%)	311/812(38.3%)	0.654
Seizure*	7/32(21.9%)	192/812(23.6%)	1.000
Encephalopathy or coma*	9/32(28.1%)	157/813(19.3%)	0.254
Elevated hemoglobin*	1/31(3.2%)	47/796(5.9%)	1.000
Elevated platelet*	1/31(3.2%)	37/796(4.6%)	1.000
Platelet count (mean SD)	249.1±107.55	268.93±100.39	0.282
One or more positive APL antibody*	8/29(27.6%)	62/692(9.0%)	0.004
Factor V and/or prothrombin mutation*	2/22(9.1%)	69/602(11.5%)	1.000
Imaging findings	15/32(46.9%)	446/809(55.1%)	0.357
Venous infarct*	6/32(18.8%)	226/809(27.9%)	0.316
Cerebral edema*	8/32(25.0%)	244/809(30.2%)	0.694
Intracranial hemorrhage	11/32(34.4%)	303/808(37.5%)	0.720
Available Follow up INR checks for Warfarin treated patients	21/26(80.8%)	467/519(90.0%)	0.666


* Fisher's exact test was performed, SD = standard deviation, INR = international normalized ratio; VTE = venous thromboembolism

Figure 1


Kaplan Meier survival analysis for recurrent venous thrombosis predictors: Black race (A), history of venous thrombosis (VTE) (B), and the presence of at least one antiphospholipid (APL) antibody (C). Non-Black race is defined as a self-reported race of Asian, White, Other, or Unknown.



Number at risk:
— 794 697 657 631 584 552 521 465 426 404 382 361 340
— 146 121 114 109 106 97 92 88 82 76 71 71 69



Number at risk:
— 843 736 695 667 622 585 552 497 456 428 405 384 362
— 104 86 80 77 71 65 62 57 53 53 49 49 48



Number at risk:
— 717 636 601 576 535 503 478 431 399 380 360 344 324
— 74 63 61 58 57 56 54 50 47 44 40 36 36

References

1. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. *Lancet Neurol*. 2007;6:162-170. doi: 10.1016/s1474-4422(07)70029-7
2. Palazzo P, Agius P, Ingrand P, Ciron J, Lamy M, Berthomet A, Cantagrel P, Neau JP. Venous Thrombotic Recurrence After Cerebral Venous Thrombosis: A Long-Term Follow-Up Study. *Stroke*. 2017;48:321-326. doi: 10.1161/strokeaha.116.015294
3. Devasagayam S, Wyatt B, Leyden J, Kleinig T. Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought: A Retrospective Population-Based Study. *Stroke*. 2016;47:2180-2182. doi: 10.1161/strokeaha.116.013617
4. Otite FO, Patel S, Sharma R, Khandwala P, Desai D, Latorre JG, Akano EO, Anikpezie N, Izzy S, Malik AM, et al. Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States. *Neurology*. 2020;95:e2200-e2213. doi: 10.1212/wnl.0000000000010598
5. Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. *Stroke*. 2012;43:3375-3377. doi: 10.1161/strokeaha.112.671453
6. Stam J. Thrombosis of the cerebral veins and sinuses. *N Engl J Med*. 2005;352:1791-1798. doi: 10.1056/NEJMra042354
7. Saposnik G, Barinagarrementeria F, Brown RD, Jr., Bushnell CD, Cucchiara B, Cushman M, deVeber G, Ferro JM, Tsai FY. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2011;42:1158-1192. doi: 10.1161/STR.0b013e31820a8364
8. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, et al. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med*. 2010;363:2499-2510. doi: 10.1056/NEJMoa1007903
9. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, et al. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med*. 2013;369:799-808. doi: 10.1056/NEJMoa1302507
10. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med*. 2009;361:2342-2352. doi: 10.1056/NEJMoa0906598
11. Miranda B, Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, Scoditti U. Venous thromboembolic events after cerebral vein thrombosis. *Stroke*. 2010;41:1901-1906. doi: 10.1161/strokeaha.110.581223
12. Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F, Investigators I. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). *Stroke*. 2004;35:664-670. doi: 10.1161/01.STR.0000117571.76197.26
13. Dentali F, Poli D, Scoditti U, Di Minno MN, De Stefano V, Siragusa S, Kostal M, Palareti G, Sartori MT, Grandone E, et al. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. *J Thromb Haemost*. 2012;10:1297-1302. doi: 10.1111/j.1538-7836.2012.04774.x

14. Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci PM. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. *Circulation*. 2010;121:2740-2746. doi: 10.1161/CIRCULATIONAHA.109.927046
15. Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhão P, Karpov D, Nagel S, Posthuma L, Roriz JM, et al. Safety and Efficacy of Dabigatran Etxilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial. *JAMA Neurol*. 2019;76:1457-1465. doi: 10.1001/jamaneurol.2019.2764
16. Yaghi S, Shu L, Bakradze E, Salehi Omran S, Giles JA, Amar JY, Henninger N, Elnazeir M, Liberman AL, Moncrieffe K, et al. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. *Stroke*. 2022:Strokeaha121037541. doi: 10.1161/strokeaha.121.037541
17. Liberman AL, Kamel H, Mullen MT, Messé SR. International Classification of Diseases, Ninth Revision (ICD-9) Diagnosis Codes Can Identify Cerebral Venous Thrombosis in Hospitalized Adults. *Neurohospitalist*. 2016;6:147-150. doi: 10.1177/1941874416648198
18. Handley JD, Emsley HC. Validation of ICD-10 codes shows intracranial venous thrombosis incidence to be higher than previously reported. *Health Inf Manag*. 2020;49:58-61. doi: 10.1177/1833358318819105
19. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, PG DEG, Koike T, Meroni PL, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost*. 2006;4:295-306. doi: 10.1111/j.1538-7836.2006.01753.x
20. Gardener H, Sacco RL, Rundek T, Battistella V, Cheung YK, Elkind MSV. Race and Ethnic Disparities in Stroke Incidence in the Northern Manhattan Study. *Stroke*. 2020;51:1064-1069. doi: 10.1161/STROKEAHA.119.028806
21. Levine DA, Duncan PW, Nguyen-Huynh MN, Ogedegbe OG. Interventions Targeting Racial/Ethnic Disparities in Stroke Prevention and Treatment. *Stroke*. 2020;51:3425-3432. doi: 10.1161/STROKEAHA.120.030427
22. Burke JF, Feng C, Skolarus LE. Divergent poststroke outcomes for black patients: Lower mortality, but greater disability. *Neurology*. 2019;93:e1664-e1674. doi: 10.1212/WNL.00000000000008391
23. Jones EM, Okpala M, Zhang X, Parsha K, Keser Z, Kim CY, Wang A, Okpala N, Jagolino A, Savitz SI, et al. Racial disparities in post-stroke functional outcomes in young patients with ischemic stroke. *J Stroke Cerebrovasc Dis*. 2020;29:104987. doi: 10.1016/j.jstrokecerebrovasdis.2020.104987
24. Camargo EC, Massaro AR, Bacheschi LA, D'Amico EA, Villaca PR, Bassitt RP, Gualandro SF, Bendit I, Scaff M. Ethnic differences in cerebral venous thrombosis. *Cerebrovasc Dis*. 2005;19:147-151. doi: 10.1159/000083247
25. Nathan AS, Geng Z, Dayoub EJ, Khatana SAM, Eberly LA, Kobayashi T, Pugliese SC, Adusumalli S, Giri J, Groeneveld PW. Racial, Ethnic, and Socioeconomic Inequities in the Prescription of Direct Oral Anticoagulants in Patients With Venous Thromboembolism in the United States. *Circ Cardiovasc Qual Outcomes*. 2019;12:e005600. doi: 10.1161/CIRCOUTCOMES.119.005600
26. Rao SR, Reisman JI, Kressin NR, Berlowitz DR, Ash AS, Ozonoff A, Miller DR, Hylek EM, Zhao S, Rose AJ. Explaining racial disparities in anticoagulation control: results from a study of patients at the Veterans Administration. *Am J Med Qual*. 2015;30:214-222. doi: 10.1177/1062860614526282

27. Miranda B, Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F, Scoditti U, Investigators I. Venous thromboembolic events after cerebral vein thrombosis. *Stroke*. 2010;41:1901-1906. doi: 10.1161/STROKEAHA.110.581223
28. Dentali F, Poli D, Scoditti U, Di Minno MN, De Stefano V, Siragusa S, Kostal M, Palareti G, Sartori MT, Grandone E, et al. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. *J Thromb Haemost*. 2012;10:1297-1302. doi: 10.1111/j.1538-7836.2012.04774.x
29. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. *Jama*. 1997;277:1305-1307.
30. Limdi NA, Beasley TM, Allison DB, Rivers CA, Acton RT. Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy. *Blood Cells Mol Dis*. 2006;37:100-106. doi: 10.1016/j.bcmd.2006.06.003
31. Elkind MSV, Lisabeth L, Howard VJ, Kleindorfer D, Howard G. Approaches to Studying Determinants of Racial-Ethnic Disparities in Stroke and Its Sequelae. *Stroke*. 2020;51:3406-3416. doi: 10.1161/strokeaha.120.030424
32. Benson RT, Koroshetz WJ. Health Disparities: Research That Matters. *Stroke*. 2022;Strokeaha121035087. doi: 10.1161/strokeaha.121.035087
33. Gateman D, Trojnar ME, Agarwal G. Time in therapeutic range: Warfarin anticoagulation for atrial fibrillation in a community-based practice. *Can Fam Physician*. 2017;63:e425-e431.
34. Cohen H, Hunt BJ, Efthymiou M, Arachchilage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. *Lancet Haematol*. 2016;3:e426-436. doi: 10.1016/s2352-3026(16)30079-5
35. Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. *Blood*. 2018;132:1365-1371. doi: 10.1182/blood-2018-04-848333
36. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, Erkan D, Krilis S, Machin S, Pengo V, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. *Lupus*. 2011;20:206-218. doi: 10.1177/0961203310395803
37. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141:e152S-e184S. doi: 10.1378/chest.11-2295
38. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M, British Committee for Standards in H. Guidelines on the investigation and management of antiphospholipid syndrome. *Br J Haematol*. 2012;157:47-58. doi: 10.1111/j.1365-2141.2012.09037.x
39. Hakoum MB, Kahale LA, Tsolakian IG, Matar CF, Yosuico VE, Terrenato I, Sperati F, Barba M, Schunemann H, Akl EA. Anticoagulation for the initial treatment of venous

- thromboembolism in people with cancer. *Cochrane Database Syst Rev.* 2018;1:CD006649. doi: 10.1002/14651858.CD006649.pub7
40. McBane RD, 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. *J Thromb Haemost.* 2020;18:411-421. doi: 10.1111/jth.14662
41. Agnelli G, Becattini C, Meyer G, Munoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. *N Engl J Med.* 2020;382:1599-1607. doi: 10.1056/NEJMoa1915103

ACCEPTED

Neurology®

Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis: Analysis of the ACTION-CVT Study

Liqi Shu, Ekaterina Bakradze, Setareh Salehi Omran, et al.
Neurology published online September 19, 2022
DOI 10.1212/WNL.0000000000201122

This information is current as of September 19, 2022

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/early/2022/09/19/WNL.0000000000201122.full
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Cerebrovascular disease/Stroke http://n.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke Inclusion, Diversity, Equity, Anti-racism, and Social Justice (IDEAS) http://n.neurology.org/cgi/collection/all_equity_diversity_and_inclusion
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2022 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

